Vericel Corp. (VCEL)

15.50
NASDAQ : Health Technology
Prev Close 15.18
Day Low/High 15.25 / 15.59
52 Wk Low/High 10.51 / 21.00
Avg Volume 474.70K
Exchange NASDAQ
Shares Outstanding 44.14M
Market Cap 670.00M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Vericel Reports First-Quarter 2017 Financial Results

Conference Call Today at 8:00am Eastern Time

Vericel Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For Ixmyelocel-T For The Treatment Of Advanced Heart Failure Due To Ischemic Dilated Cardiomyopathy

Ixmyelocel-T is the First Therapy to Receive the RMAT Designation for the Treatment of a Serious Cardiovascular Disease

Vericel Announces Appointment Of Michael Halpin As Senior Vice President, Quality And Regulatory Affairs

Accomplished Industry Veteran Brings Extensive Quality and Regulatory Affairs Experience in Cell and Gene Therapies and Medical Devices

First Week of VCEL March 17th Options Trading

First Week of VCEL March 17th Options Trading

Investors in Vericel Corp saw new options begin trading this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VCEL options chain for the new March 17th contracts and identified the following call contract of particular interest.

TheStreet Quant Rating: D (Sell)